Testing effectiveness (Phase 2)Study completedNCT03647839
What this trial is testing
Modulation Of The Tumour Microenvironment Using Either Vascular Disrupting Agents or STAT3 Inhibition in Order to Synergise With PD1 Inhibition in Microsatellite Stable, Refractory Colorectal Cancer
Who this might be right for
Colorectal Cancer Metastatic
Australasian Gastro-Intestinal Trials Group 90